Ad
related to: latest developments in schizophrenia center of pennsylvania city
Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
In the previous study, luvadaxistat failed to meet the main goal of change from baseline in negative symptoms of schizophrenia, however, it met the secondary goal of improving cognitive performance.
N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...
RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...
Jeffrey Alan Lieberman (born 1948) is an American psychiatrist who specializes in schizophrenia and related psychoses and their associated neuroscience (biology) and pharmacological treatment (psychiatric drugs).
He is the original author of the landmark neurodevelopmental hypothesis of schizophrenia (first published in The Neurology of Schizophrenia, Elsevier, 1986) [12] and in the more cited reference, Arch Gen Psychiatry 1987, (the most cited publication [>4100 citations] about the biology of schizophrenia in Google Scholar).
And while antipsychotics can help schizophrenia’s “positive” symptoms, such as hallucinations, they have a minimal impact on the “negative” symptoms, which are arguably more devastating. People who have schizophrenia can lose the ability to focus, to sustain effort, to carry on a conversation or to maintain eye contact.
Cannabis use may be a contributory factor in the development of schizophrenia, potentially increasing the risk of the disease in those who are already at risk. [122] [123] [124] The increased risk may require the presence of certain genes within an individual. [22] Its use is associated with doubling the rate. [125]
Ad
related to: latest developments in schizophrenia center of pennsylvania city